Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Cesca Therapeutics Inc.

  • Chris Xu, Cesca Therapeutics Inc.

Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company has launched an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market.

  • Date:Monday, February 11
  • Time:10:30 AM - 10:45 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Submission ID:23292
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:To provide an update on the direction of the Company such as strategic initiatives, products/markets
  • Company Website:www.cescatherapeutics.com
  • Company HQ City:Rancho Cordva
  • Company HQ State:California
  • Company HQ Country:United States
  • Market Cap:6,029,551
  • Ticker:KOOL
  • Exchange:NASDAQ
  • CEO/Top Company Official:Chris Xu
  • Year Founded:1986
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development:X-Series Product Line
  • Development Phase of Primary Product:Multiple Products in Market
Speakers
Chris Xu
Cesca Therapeutics Inc.
Back